College of Pharmacy and Institute of Drug Research and Development, Chungnam National University, Daejeon 305-764, Republic of Korea.
Bioorg Med Chem Lett. 2012 Jul 15;22(14):4523-7. doi: 10.1016/j.bmcl.2012.06.001. Epub 2012 Jun 7.
To investigate the anti-proliferative effect of a newly discovered NF-kB inhibitor, 6,6-dimethyl-2-(phenylimino)-6,7-dihydrobenzo[d][1,3]oxathiol-4(5H)-one (1a), a series of its analogs (1b-n) were prepared and evaluated for their NF-κB inhibition and anti-proliferative activity against various human cancer cell lines. Slight variation of hydrophobicity by replacement of dimethyl group of 1a at 6-position with bulky isopropyl group and introduction of para-fluoro substitution on 2-phenyl group showed good NF-κB inhibitory activity and anti-proliferative activity. However, excessive increase in hydrophobicity with 2,4,6-trichloro substituents on phenyl group resulted in the loss of both the activities. From the SAR results, 2-phenylimino-6,7-dihydrobenzo[d][1,3]oxathiol-4(5H)-one was identified as the lead scaffold for investigating new anticancer agent through inactivation of NF-κB.
为了研究一种新发现的 NF-κB 抑制剂的抗增殖作用,我们合成了一系列其类似物(1b-n),并评估了它们对各种人癌细胞系的 NF-κB 抑制和抗增殖活性。通过用较大的异丙基基团替代 1a 在 6 位上的二甲基基团,以及在 2-苯基上引入对氟取代基,对化合物 1a 的疏水性进行了轻微的改变,结果显示出良好的 NF-κB 抑制活性和抗增殖活性。然而,在苯基上引入 2,4,6-三氯取代基会导致疏水性的过度增加,从而使这两种活性都丧失。根据 SAR 结果,2-苯基亚氨基-6,7-二氢苯并[d][1,3]恶硫酚-4(5H)-酮被确定为通过使 NF-κB 失活来研究新型抗癌剂的先导骨架。